NCT00299650

Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 340 (estimated)
• Sponsor: Assistance Publique Hopitaux De Marseille · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. The aim of the study is to show a reduction of the mortality rate of ARDS patients.

Detailed description

The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. It has been recently demonstrated that a systematic 48-h infusion of NMBA is associated with a significant improvement in oxygenation as compared with a control group (Gainnier et al., Crit Care Med 2004). Moreover, a trend towards a reduction in the mortality rate has been observed. The aim of the study is to show a reduction of the mortality rate of ARDS patients.

Conditions

• ARDS

Interventions

Type	Name	Description
DRUG	cisatracurium
DRUG	Placebo	physiological serum infusion
DRUG	Cisatracurium besilate	Cisatracurium besilate infusion (900mg/day)

Timeline

• Start date: 2006-03-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2006-03-07
• Last updated: 2008-10-10

Locations

20 sites across 1 country: France